Florence Joly

5.1k total citations · 1 hit paper
56 papers, 1.4k citations indexed

About

Florence Joly is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Florence Joly has authored 56 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Reproductive Medicine, 23 papers in Oncology and 18 papers in Surgery. Recurrent topics in Florence Joly's work include Ovarian cancer diagnosis and treatment (26 papers), PARP inhibition in cancer therapy (13 papers) and Intraperitoneal and Appendiceal Malignancies (9 papers). Florence Joly is often cited by papers focused on Ovarian cancer diagnosis and treatment (26 papers), PARP inhibition in cancer therapy (13 papers) and Intraperitoneal and Appendiceal Malignancies (9 papers). Florence Joly collaborates with scholars based in France, Luxembourg and Italy. Florence Joly's co-authors include Andreas du Bois, Éric Pujade-Lauraine, Gunnar B. Kristensen, Jalid Sehouli, Christian Jackisch, Alain Lortholary, Annamaria Ferrero, Ignace Vergote, Chris Brown and Birgit Volgger and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Florence Joly

48 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

2010 410 citations Éric Pujade-Lauraine, Uwe Wagner et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Florence Joly France	15	534	483	381	245	243	56	1.4k
A. Nawa Japan	21	325 0.6×	385 0.8×	155 0.4×	140 0.6×	461 1.9×	30	1.3k
Yuji Takei Japan	21	337 0.6×	339 0.7×	119 0.3×	347 1.4×	394 1.6×	75	1.2k
Esther Elishaev United States	24	528 1.0×	498 1.0×	195 0.5×	454 1.9×	582 2.4×	70	1.8k
E. Dreher Switzerland	20	300 0.6×	213 0.4×	313 0.8×	262 1.1×	302 1.2×	63	1.2k
Daichi Maeda Japan	28	488 0.9×	449 0.9×	359 0.9×	245 1.0×	1.0k 4.1×	91	2.5k
Yasushi Saga Japan	22	273 0.5×	354 0.7×	104 0.3×	168 0.7×	670 2.8×	66	1.4k
W. Michael Hogan United States	18	516 1.0×	375 0.8×	304 0.8×	362 1.5×	254 1.0×	33	1.3k
Shinichi Komiyama Japan	16	380 0.7×	213 0.4×	238 0.6×	234 1.0×	189 0.8×	76	882
James P. LaPolla United States	18	607 1.1×	453 0.9×	400 1.0×	472 1.9×	486 2.0×	33	1.7k
Matteo Morotti Italy	24	979 1.8×	309 0.6×	293 0.8×	712 2.9×	641 2.6×	60	2.1k

Countries citing papers authored by Florence Joly

Since Specialization

Citations

This map shows the geographic impact of Florence Joly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence Joly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence Joly more than expected).

Fields of papers citing papers by Florence Joly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence Joly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence Joly. The network helps show where Florence Joly may publish in the future.

Co-authorship network of co-authors of Florence Joly

This figure shows the co-authorship network connecting the top 25 collaborators of Florence Joly. A scholar is included among the top collaborators of Florence Joly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florence Joly. Florence Joly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Piffoux, Max, Alexandra Léary, Philippe Follana, et al.. (2025). Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial. Nature Communications. 16(1). 1821–1821. 1 indexed citations

Elie, Nicolas, Pierre‐Marie Morice, Louis‐Bastien Weiswald, et al.. (2025). Automated Scoring to Assess RAD51-Mediated Homologous Recombination in Ovarian Patient-Derived Tumor Organoids. Laboratory Investigation. 105(4). 104097–104097. 1 indexed citations

Lindemann, Kristina, Dominique Berton-Rigaud, Jalid Sehouli, et al.. (2025). NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. Gynecologic Oncology. 199. 79–87.

Franzoi, Maria Alice, Julie Havas, Davide Soldato, et al.. (2024). Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes. ESMO Open. 9(2). 102236–102236. 14 indexed citations

Culine, Stéphane, Valentin Harter, Clémentine Krucker, et al.. (2023). Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Cancers. 15(6). 1742–1742. 6 indexed citations

Alexandre, Jérôme, Marie‐Aude Le Frère‐Belda, Antoine Angelergues, et al.. (2023). Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute. Bulletin du Cancer. 110(6). 6S34–6S43.

Treilleux, Isabelle, et al.. (2023). Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Diagnostic histomoléculaire des carcinomes de l'endomètre. Bulletin du Cancer. 110(6). 6S10–6S19.

Joly, Florence, Dominique Vaur, Bernard Asselain, et al.. (2022). 2022-RA-922-ESGO Histo-molecular characteristics of platinum-sensitive advanced endometrial cancer: data issued from the population included in the GINECO UTOLA study. International Journal of Gynecological Cancer. 32. A118–A119.

Sabatier, Renaud, Frédérique Rousseau, Florence Joly, et al.. (2022). Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial. European Journal of Cancer. 181. 42–52. 13 indexed citations

10.

Woopen, Hannah, Jalid Sehouli, Alison Davis, et al.. (2022). GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. Cancer Treatment Reviews. 107. 102396–102396. 7 indexed citations

11.

Classe, Jean‐Marc, Florence Joly, Fabrice Lécuru, et al.. (2021). Prise en charge chirurgicale du cancer épithélial de l’ovaire – première ligne et première rechute. Bulletin du Cancer. 108(9). S13–S21. 3 indexed citations

12.

Pfister, Christian, Gwénaëlle Gravis, Aude Fléchon, et al.. (2020). Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. European Urology. 79(2). 214–221. 150 indexed citations

13.

Joly, Florence, et al.. (2019). Effets secondaires de la chimiothérapie des cancers testiculaires et suivi de l’après cancer. Bulletin du Cancer. 106(9). 805–811. 5 indexed citations

14.

Treilleux, Isabelle, Coline Couillault, Daniel Pissaloux, et al.. (2018). Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathologica. 135(4). 569–579. 75 indexed citations

15.

Pujade-Lauraine, Éric, Uwe Wagner, Val Gebski, et al.. (2010). Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology. 28(20). 3323–3329. 410 indexed citations breakdown →

16.

Shanker, Anil, Grégory Verdeil, Michel Buferne, et al.. (2007). CD8 T Cell Help for Innate Antitumor Immunity. The Journal of Immunology. 179(10). 6651–6662. 69 indexed citations

17.

Bourgeois, Hugues, Florence Joly, Éric Pujade-Lauraine, et al.. (2006). Phase I Study of Pegylated Liposomal Doxorubicin in Combination With Ifosfamide in Pretreated Ovarian Cancer Patients. American Journal of Clinical Oncology. 29(4). 399–404. 9 indexed citations

18.

Puthier, Denis, Florence Joly, Magali Irla, et al.. (2004). A General Survey of Thymocyte Differentiation by Transcriptional Analysis of Knockout Mouse Models. The Journal of Immunology. 173(10). 6109–6118. 24 indexed citations

19.

Coré, Nathalie, Florence Joly, Annie Boned, & Malek Djabali. (2004). Disruption of E2F signaling suppresses the INK4a-induced proliferative defect in M33-deficient mice. Oncogene. 23(46). 7660–7668. 22 indexed citations

20.

Joly, Florence, Jean‐François Héron, Pierre Kerbrat, et al.. (2000). High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecologic Oncology. 78(3). 361–368. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact